Thromboembolic Risk Factors in Patients Undergoing Kidney Transplant: Implication of Abnormally Short Activated Partial Thromboplastin Time
|
|
- Melvin Johnston
- 6 years ago
- Views:
Transcription
1 396 Annals of Clinical & Laboratory Science, vol. 33, no. 4, 2003 Thromboembolic Risk Factors in Patients Undergoing Kidney Transplant: Implication of Abnormally Short Activated Partial Thromboplastin Time Nabil G. Guirguis, 1 Chad Eicher, 1 Lynette Hock, 2 James Lynch, 2 Vicki D. Graham, 3 P. R. Rajagopalan, 3 Amal Guirguis, 3 and John Lazarchick 3 1 Internal Medicine Department and 2 Preventive and Societal Medicine Department, University of Nebraska Medical Center, Omaha, Nebraska; 3 Pathology and Transplantation Departments, Medical University of South Carolina, Charleston, South Carolina Abstract. This study was designed to examine the relationship of short activated partial thromboplastin time (aptt) and prothrombin time (PT) to the incidence of thromboembolic events, hereditary and acquired coagulation defects associated with an increased risk of thrombosis, or cardiovascular diseases in patients undergoing renal transplantation. The prevalence of these conditions in our patients (n = 436) was 55%. Forty-two percent of the patients had short aptt or PT. Multivariate analysis revealed that patients with short aptt have an odds ratio (OR) = 2.15, 95% Confidence Interval (CI) ( ) (p =0.0042), and for patients with short PT, an OR = 2.01, 95% CI ( ) (p = 0.052). Our study also suggests that other risk factors, including non-white ethnicity (98% blacks), OR =1.64, 95% CI ( ) (p = 0.047), diabetes mellitus, OR = 2.62, 95% CI ( ) (P = 0.028), and autosomal dominant polycystic kidney disease (ADPKD) (p <0.0001). Short aptt results, or probably short PT results, pre- or post-transplantation may be associated with increased risks for thromboembolism. (received 23 June 2003; accepted 2 July 2003) Keywords: activated partial thromboplastin time, prothrombin time thromboembolism, renal transplantation Introduction Address correspondence to: John Lazarchick, M.D., Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 165 Ashley Avenue, Suite 309, P.O. Box , Charleston, SC 29425, USA; tel ; fax ; lazarj@musc.edu. The most common causes of early renal allograft failure are related to the vasculature, with 1 / 3 to 1 / 2 of early graft losses due to renal graft thrombosis [1]. The incidence of venous thromboembolism in the transplant population is variable, depending on the definition used in the studies [2,3]. Humor et al [4] reported an incidence of %. The incidence of pulmonary embolism was reported to be 2-14%, with a mortality rate of % [4,5]. Inherited and acquired causes of hypercoagulable states along with other secondary causes predispose the patients to thromboembolic diseases. Risk factors for thromboembolic diseases include the presence of factor V Leiden mutation, protein S or C deficiency, lupus anticoagulant, antiphospholipid antibody, prothrombin 20210A gene mutation, anti-thrombin III deficiency, and polymorphism of plasminogen activator inhibitor-1 gene (4G/4G) in the transplanted kidney [2,3,6-12]. Heparin cofactor II deficiency, on the other hand, has been shown not to be a risk factor for thrombosis in renal allograft recipients [13]. In contrast to merely identifying a specific hypercoagulable condition as a risk factor for thrombosis, a recently published case study reported a significantly short aptt (activated partial thromboplastin time) in a renal allograft recipient who was positive for the factor V Leiden mutation and who subsequently developed renal vein and artery thrombosis along with the loss of her graft [14]. This case suggested a possible association between an abnormality in a common laboratory test (ie, the aptt) and development of thrombosis in renal graft recipients. The report prompted the present study of the significance of short aptt and PT test results in renal transplant patients /03/0400/0396 $ by the Association of Clinical Scientists, Inc.
2 Significance of short aptt in renal transplant patients 397 Material and Methods Patients. Patients (n = 598) who received cadaveric (75%) or living-related (25%) kidney grafts between January 1994 and January 1999 in the Transplant Center of The Medical University of South Carolina were investigated. At the time of data collection, the median elapsed period post-transplant was 24 mo. Of the patients, 162 were excluded because they did not have sufficient laboratory tests or sufficient clinical findings to be placed in the case or the control groups. The remaining patients were stratified pre-analysis to 241 patients in the case group that had thromboembolic diseases, coagulation defects, or cardiovascular diseases, and 195 in the control group that had no thromboembolic diseases, cardiovascular diseases, or other conditions that might increase the risk of thrombosis. Patients in the case group had at least one of the following conditions: deep venous thrombosis, recurrent access clotting, pulmonary embolism, kidney graft thrombosis, allograft pancreas thrombosis, previous use of warfarin in the absence of atrial fibrillation, hemolytic uremic syndrome, coagulation defect (protein C or protein S deficiency, antithrombin III deficiency), or objective evidence of myocardial insult (defined as a history of myocardial infarction, coronary artery bypass surgery, or coronary angioplasty). Patients in the control group did not have the above conditions or any other conditions that might increase the risk of thromboembolism. These conditions included pulmonary hypertension, questionable ventilation perfusion scan, chest pain, foot gangrene, calciphylaxis, cerebrovascular accident, extremity embolism, malignancy, foot amputation, peripheral arterial disease, vascular insufficiency of the intestine, abnormal renal transplant scan consistent with partial infarction, or avascular necrosis of hip joints. History of coumadin use was used as indirect evidence of a thrombotic event, after excluding the patients with atrial fibrillation. Methods. This study investigated the relationships of short activated partial thromboplastin (aptt) and prothrombin (PT) times to the thromboembolic events cited above, from the time that the patients were in renal failure to the time post-transplantation. The duration of the study was up to 9 years. All the patients who received kidney, or kidney and pancreas, transplants between January 1994 and January 1999 were included. Retrospectively, the hospital charts, electronic records in the patient information system, and the ICD-9 codes were scrutinized since Short aptt and PT results during this time period were recorded, as well as the laboratory reference ranges. The cases and controls were sampled during concurrent time periods. Specimens were collected from the cases from June 1993 to February 1999 and from the controls from June 1993 to January The median number of days between assay of both PT and aptt and transplant was 0, ranging from 3.6 yr pre- to 4.9 yr post-transplant for aptt, (interquartile range = 12 days), and 4.6 yr pre- to 5.1 yr post-transplant for PT (interquartile range = 1 day). The normal reference ranges for aptt and PT test results were modified periodically as reagent lots for these assays were changed in the hematology laboratory, based upon a routine protocol with blood samples from healthy volunteers (n = 20-40). The case and control samples were all analyzed at the time of sample collection and no values were obtained on frozen/thawed specimens. Measurements were performed with a coagulation analyzer (MLA 1600 instrument) throughout this study. Correlation studies were done with any new reagent compared to the old reagent. The aptt and the PT test results were considered to be short if they were less than the lower limits of the reference ranges. It is unlikely that variations in the sampling process or assay technique would bias the association under investigation, because no difference was found between the cases and controls in respect to the laboratory control values (Table 1). Statistical analysis. SAS software, version 8, was used for the data analysis. For comparison of groups, t-tests, Wilcoxon s rank sum test, and Fisher s exact test were used for univariate analysis. For multivariate analysis, multiple logistic regression was used. All tests were two-sided. The level of statistical significance was defined as p <0.05. The patients race was classified as either as white or non-white.
3 398 Annals of Clinical & Laboratory Science Table 1. Univariate analysis of the renal transplant patients characteristics and parameters. Characteristic or parameter Comparison Cases Controls p value n (%) n (%) Number (total = 436) 241 (55%) 195 (45%) Laboratory lowest reference range of PT median range Laboratory lowest reference range of aptt median range Age at renal transplant (yr) mean ± SD 42.0 ± ± Gender female 101 (42%) 96 (49%) 0.15 Race non-white 156 (65%) 107 (55%) Diabetes mellitus present 34 (14%) 12 (6%) * Assay for CMV antibodies positive 190 (80%) 135 (72%) Autosomal dominant polycystic kidney disease present 64 (27%) 18 (9%) <0.0001* *Patients in the case group had significantly higher prevalences of diabetes mellitus and autosomal dominant polycystic kidney disease (ADPKD) than the patients in the control group (p <0.05). The non-white group included 3 hispanics, 257 blacks, and 3 others. Results Table 1 contains demographic information for the cases and controls. Patients in the case group had higher prevalences of diabetes mellitus and ADPKD (p = , and <0.0001, respectively). The prevalence of at least one condition described in the case group (thromboembolic diseases, coagulation defects, or cardiovascular diseases) was 55%. Forty two percent of the entire group had a short aptt or PT. The prevalence of short aptt was 35% and that of short PT was 14%. Seven percent of the patients had both short aptt and short PT results. The prevalence of short aptt in the case and control groups was 39% and 29%, respectively. The prevalence of short PT in the case and control groups was 17% and 11%, respectively. When the prevalences of the short aptt and short PT in the case and the control groups were compared, short aptt were found to be greater in the cases (p = 0.020) and short PT was marginally greater (p=0.073) (Table 2). When the median aptt and PT of the lowest laboratory reference range values for the cases were compared to the lowest laboratory reference range values for the controls, there were no significant differences (Table 1). On the other hand, PT values for the cases (median = 11.2 sec) were significantly shorter than for the controls (median = 11.4 sec, p = 0.043). A marginal difference was found for the aptt (p = 0.072). Since some of the cases were receiving coumadin, the difference between cases and controls may be underestimated. The proportions and values of cases with normal PT and aptt would likely be lower in the absence of treatment. After adjustment for age at transplant, race (white versus non-white), gender, and diabetes mellitus, the odds ratio (OR) as an independent risk factor for thromboembolic diseases in patients with short aptt was 2.15, 95% CI ( ) (p = ), and in patients with short PT was 2.01, 95% CI ( ) (p = 0.052). Other OR values were as follows: in males = 1.76, 95% CI ( ) (p = 0.024), in non-white subjects (98% blacks) = 1.64, 95% CI ( ) (p = 0.047), and for in patients with diabetes mellitus = 2.62 ( ) (p = 0.028) (Table 3). The association
4 Significance of short aptt in renal transplant patients 399 Table 2. Comparisons between the prevalences of short PT and short aptt results in the cases and controls. Parameter Comparison Cases Controls p value n (%) n (%) Short PT (count) less than normal 41 (17%) 21 (11%) normal 199 (83%) 174 (89%) Short aptt (count) less than normal 95 (39%) 56 (29%) 0.020* normal 146 (61%) 139 (71%) *Patients in the case group had significantly higher prevalence of short aptt results than the patients in the control group (p <0.05). of autosomal dominant polycystic kidney disease (ADPKD) was highly significant in the univariate analysis (p <0.0001) (Table 1). Discussion Assays for aptt and PT are routinely performed on patients before renal transplant surgery to check for an increased risk for bleeding, but the significance of short aptt and PT results are not fully understood in this population. This paper highlights short aptt and/or PT results as indicators of increased risk for thromboembolic events in this group. This study shows that the prevalence of thromboembolic diseases, hereditary or acquired coagulation defects associated with increased risk for thrombosis, or cardiovascular diseases is very high in this population. Furthermore, it suggests that they are related to excess morbidity and probably to excess mortality observed in these patients. This paper considers other risk factors including non-white race, ADPKD, and diabetes. Diabetes mellitus was found by Ohio et al [15] to be associated with renal vein thrombosis in the kidney transplant population. The implications of thrombosis are grave and sometimes result in loss of the graft [1,14]. Moreover, the risk factors for thromboembolic diseases might be related to acute rejection and probably to long-term graft survival. A retrospective study by Heidenreich et al [16] found a relationship between hypercoagulable state risk factors and acute rejection in renal allograft recipients. Other investigators have studied the potential association between short aptt and risk of thrombosis in non-transplant populations. McKenna et al [17] conducted a prospective clinical Table 3. Multivariate analysis using logistic regression. Variables Odds ratio 95% CI p value Short PT Short appt * Age (1 yr increase) Non-white * Male * Diabetes mellitus * * p < After correcting for other risk factors, short aptt is an independent risk factor for thromboembolic diseases in renal transplant patients. trial examining a short aptt result as a risk factor for thrombosis. The study showed 10-fold increased risk of thromboembolism in study subjects with a short aptt. Edson et al [18] reported that short aptt results are indicative of increased levels of procoagulants, and the increased procoagulants were associated with thrombosis. Landi et al [19] found that short aptt results were associated with deep venous thromboses in acute stroke patients, while Gallus et al [20] found that short aptt results preand post-operation were predictive of post-operative thrombosis. In contrast to these studies, Belliveau [21] reported that upon review of clinical records it was found that patients with extremely short aptt results had a history of spontaneous bleeding. A recent study by Korte et al [22] examined the relationship between short aptt results and thrombosis. They found in a general patient population that subjects with short aptt results were at increased risk for thromboembolism.
5 400 Annals of Clinical & Laboratory Science Our previous case report [14] suggested that short aptt might be a risk factor for thrombosis in kidney transplant patients. The current study supports the importance of short aptt results, and possibly of short PT results, pre- or posttransplantation, as risk factors for thromboembolic diseases, coagulation defects, or cardiovascular diseases in the renal transplant population. Short aptt results, or probably short PT results, pre- or post-transplantation appear to carry increased risks for thromboembolic diseases or cardiovascular diseases. These are prevalent problems that are associated with high morbidity and probably with high mortality in the renal transplant population. Further investigations are needed to characterize the pre- and the post-transplant patients according to their risk factors. References 1. Bakir N, Sluiter WJ, Ploeg RJ, van Son WJ, Tegzess AM. Primary renal graft thrombosis. Nephrol Dial Transplant 1996;11: Oh J, Schaefer F, Veldmann A, Nowak G, Nowak-Gottl U, Tonshoff B, et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999;68: Ekberg H, Svensson PJ, Simanaitis M, Dahlback B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000;69: Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, Dunn DL, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998;65: Arnadottir M, Bergentz SE, Bergqvist D, Husberg B, Konrad P, Lindholm T. Thromboembolic complications after renal transplantation: a retrospective analysis. World J Surg 1983;7: Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997;64: Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336: Vaidya S, Wang CC, Gugliuzza C, Fish JC. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998;12: Knight RJ, Schanzer H, Rand JH, Burrows L. Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Transplantation 1995;60: Wagenknecht DR, Fastenau DR, Torry RJ, Carter CB, Haag BW, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft. Transplant Proc 1999;31: Wang Y, Turner N, An SF, Fleming KA, Thompson EM. Gene expression of plasminogen activator inhibitor 1 in transplant kidneys complicated by renal vein thrombosis: a combined study by in-situ hybridization and immunohistochemistry. Nephrol Dial Transplant 1994;9: Penny MJ, Nankivell BJ, Disney AP, Byth K, Chapman JR. Renal graft thrombosis. A survey of 134 consecutive cases. Transplantation 1994;58: Toulon P, Moulonguet-Doleris L, Costa JM, Aiach M. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemost 1991;65: Guirguis N, Budisavljevic MN, Self S, Rajagopalan PR, Lazarchick J. Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation. Ann Clin Lab Sci 2000;30: Ojo AO, Hanson JA, Wolfe RA, Agodoa LY, Leavey SF, Leichtman A, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999;55: Heidenreich S, Dercken C, August C, Koch HG, Nowak- Gottl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998;9: McKenna R, Bachmann F, Miro-Quesada M. Thromboembolism in patients with abnormally short activated partial thromboplastin time. Thromb Haemost 1977;38: Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70: Landi G, D Angelo A, Boccardi E, Candelise L, Mannucci PM, Morabito A, et al. Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. Arch Neurol 1992;49: Gallus AS, Hirsh J, Gent M. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet 1973;2: Belliveau RR. Extremely shortened activated partial thromboplastin times. JAMA 1980;243: Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000;113:
ORIGINAL INVESTIGATION. Prediction of Adverse Events and Poor Prognosis by Low Abnormal Values
ORIGINAL INVESTIGATION Partial Thromboplastin Time Prediction of Adverse Events and Poor Prognosis by Low Abnormal Values Neena M. Reddy, MS; Stephen W. Hall, MD; F. Roy MacKintosh, MD, PhD Background:
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationVenous thromboembolism (VTE) consists of deep vein
Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD
More informationDEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION
DEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION THE RISK OF RECURRENT DEEP VENOUS THROMBOSIS AMONG HETEROZYGOUS CARRIERS OF BOTH FACTOR V LEIDEN AND THE G20210A
More informationJordan M. Garrison, MD FACS, FASMBS
Jordan M. Garrison, MD FACS, FASMBS Peripheral Arterial Disease (PAD) Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous reflux Disease Varicose Veins Chronic Venous Stasis Ulcer Disease
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationChapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy
Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer
More informationAbnormally Short Activated Partial Thromboplastin Times Are Related to Elevated Plasma Levels of TAT, F1+2, D-Dimer and FVIII:C
Pathophysiology of Haemostasis andthrombosis Original Paper Pathophysiol Haemost Thromb 2002;32:137 142 DOI: 10.1159/000065217 Received: January 28, 2002 Accepted in revised form: June 28, 2002 Abnormally
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationLaboratory Evaluation of Venous Thrombosis Risk
Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic
More informationThe Risk of Recurrent Venous Thromboembolism in Men and Women
The new england journal of medicine original article The Risk of Recurrent Venous Thromboembolism in Men and Women Paul A. Kyrle, M.D., Erich Minar, M.D., Christine Bialonczyk, M.D., Mirko Hirschl, M.D.,
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationRECURRENT VENOUS THROMBOEMBOLISM AND MUTATION IN THE GENE FOR FACTOR V
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH AN Arg 506 Gln MUTATION IN THE GENE FOR FACTOR V (FACTOR V LEIDEN) PAOLO SIMIONI, M.D., PAOLO PRANDONI, M.D., PH.D., ANTHONIE W.A. LENSING,
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationOptimal Utilization of Thrombophilia Testing
Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine
More informationThe etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A.
UvA-DARE (Digital Academic Repository) The etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A. Link to publication Citation for published version (APA): Kraaijenhagen, R. A.
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationIRB protocol Yair Lev, MD 11/25/08
IRB protocol Yair Lev, MD 11/25/08 Abdominal and Pelvic CT as a screening modality for occult malignant disease in unprovoked Venous Thromboembolism: A randomized, controlled prospective study. A. Study
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationCost-effectiveness of minimally invasive coronary artery bypass surgery Arom K V, Emery R W, Flavin T F, Petersen R J
Cost-effectiveness of minimally invasive coronary artery bypass surgery Arom K V, Emery R W, Flavin T F, Petersen R J Record Status This is a critical abstract of an economic evaluation that meets the
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationG20210A prothrombin gene mutation identified in patients with venous leg ulcers
J.Cell.Mol.Med. Vol 5, No 4, 2001 pp. 397-401 G20210A prothrombin gene mutation identified in patients with venous leg ulcers Gh. Jebeleanu, Lucia Procopciuc * Department of Medical Biochemistry, University
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationWhy is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager
Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient in addition
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationChoosing Wisely: If, When, What, and Who to Test for Thrombophilia
Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationThrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation
2700 E.C. Lorenz et al. Nephrol Dial Transplant (2011) 26: 2700 2705 doi: 10.1093/ndt/gfq791 Advance Access publication 1 February 2011 Thrombophilic factors in Stage V chronic kidney disease patients
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationThe risk of venous thromboembolism is markedly elevated in patients with diabetes
Diabetologia (2005) 48: 1017 1021 DOI 10.1007/s00125-005-1715-5 ARTICLE V. Petrauskiene. M. Falk. I. Waernbaum. M. Norberg. J. W. Eriksson The risk of venous thromboembolism is markedly elevated in patients
More informationStability of prothrombin time and activated partial thromboplastin time tests under different storage conditions
Clinica Chimica Acta 300 (2000) 13 21 www.elsevier.com/ locate/ clinchim Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions L.V. Rao *, A.O.
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationVascular Protection: Preventing Thrombotic Complications of VTE and PAD
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationIn which direction, and how aggressively,
Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Evaluating idiopathic venous thromboembolism: What is necessary, what is not Charles F. S. Locke, MD Johns Hopkins Community
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationPreoperative Management of Patients Receiving Antithrombotics
Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing
More informationAfter a first episode of acute venous thromboembolism
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationPrevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan
Clinical Studies Prevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan Kazunori HAYASHI, MD, Takahito SONE,1 MD, Junichiro KONDOH,1 MD, Hideyuki TSUBOI,1 MD, Hiromi SASSA,1
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationThrombophilia due to Activated Protein C Resistance
CASE REPORT JIACM 2005; 6(3): 244-7 Thrombophilia due to Activated Protein C Resistance Kamal S Saini*, Mrinal M Patnaik*, Vidya S Nagar**, Alaka K Deshpande*** Abstract Thrombophilia is a hereditary or
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationVTE Risk Assessment. Challenges of Hemostasis in Cancer Patients. Cihan Ay, MD Associate Professor
Challenges of Hemostasis in Cancer Patients VTE Risk Assessment Cihan Ay, MD Associate Professor Clinical Division of Haematology and Haemostaseology Department of Medicine I, Comprehensive Cancer Center
More informationLaboratory Markers in the Diagnosis of Venous Thromboembolism
Laboratory Markers in the Diagnosis of Venous Thromboembolism Joseph A. Caprini, MD, Catherine J. Glase, BS, Christopher B. Anderson, Karen Hathaway, BS Department of Surgery Evanston Northwestern Healthcare,
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationA Comparative Analysisof Male versus Female Breast Cancer in the ACS NSQIP Database
A Comparative Analysisof Male versus Female Breast Cancer in the ACS NSQIP Database Lindsay Petersen, MD Rush University Medical Center Chicago, IL I would like to recognize my coauthors: Andrea Madrigrano,
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationTesting for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness
Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness analysis Eckman M H, Singh S K, Erban J K, Kao G Record Status This is a critical abstract of an economic
More informationResearch Article Comparison of Chemical and Mechanical Prophylaxis of Venous Thromboembolism in Nonsurgical Mechanically Ventilated Patients
rombosis Volume 2015, Article ID 849142, 6 pages http://dx.doi.org/10.1155/2015/849142 Research Article Comparison of Chemical and Mechanical Prophylaxis of Venous Thromboembolism in Nonsurgical Mechanically
More informationN ATT. The Genetics of Thrombophilia. Written by: Elizabeth Varga, M.S.*
N ATT The National Alliance for Thrombosis and Thrombophilia The Genetics of Thrombophilia Written by: Elizabeth Varga, M.S.* Edited by: Amy Sturm, M.S., CGC* *Genetic Counselor, The Adult Medical Genetics
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationElevated Factor XI Activity Levels Are Associated With an Increased Odds Ratio for Cerebrovascular Events
Coagulation and Transfusion Medicine / FACTOR XI AND RISK OF STROKE Elevated Factor XI Activity Levels Are Associated With an Increased Odds Ratio for Cerebrovascular Events David T. Yang, MD, 1 Michele
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationEPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas
EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer
More informationHeparin induced thrombocytopenia in the critically ill: How to interpret anti- PF4 antibody test results
Heparin induced thrombocytopenia in the critically ill: How to interpret anti- PF4 antibody test results Daniel H. Kett, M.D. Professor of Clinical Medicine Director MICU, Jackson Memorial Hospital University
More informationResults from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine
Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE
More information